Exploring supportive care and information needs through a proposed eHealth application among melanoma patients undergoing systemic therapy: a qualitative study.

Publication date: May 19, 2022

During and after systemic therapy, patients with high risk and advanced melanoma experience challenges regarding cancer-related symptoms, treatment-related adverse events, and an impact of these symptoms on their physical and psychosocial well-being. Few studies have investigated the specific needs of these patients and the potential role of eHealth applications in meeting those needs. To explore the supportive care and information needs of high risk and advanced melanoma patients, and how these needs can be supported by eHealth applications. In this qualitative study, semi-structured interviews with high risk and advanced melanoma patients during or after systemic treatment were conducted to understand their needs and requirements as possible end-users of mobile eHealth applications. Interview transcripts were independently coded and thematically analyzed. Thirteen participants consented to be interviewed, aged 31 to 71 years. Nearly all patients (n = 12, 92%) experienced unmet information and supportive care needs during and after active treatment. Patients expected to value eHealth applications that facilitate information gathering, wellbeing interventions, and symptom management. The majority of patients (n = 10, 77%) anticipated various advantages from using an eHealth application, including increased autonomy, higher quality of life, and improved disease self-management. High risk and advanced melanoma patients have unmet supportive care and information needs during and after systemic treatment. The use of eHealth applications might be an effective way to meet these unmet needs. Patients anticipate a variety of advantages from using these applications, including deriving various benefits from the use of these applications, such as enhanced autonomy.

Open Access PDF

Concepts Keywords
71years Telemedicine
Cancer Cancer
Interviews Therapy
Wellbeing Melanoma
Related symptoms treatment
Mobile eHealth applications
Advantages applications
EHealth applications
Self management
Life sciences
Health sciences
Benefits applications


Type Source Name
disease MESH chronic diseases
disease MESH risk factors
disease MESH lymphoma
disease MESH noma
disease MESH development
disease MESH literacy
drug DRUGBANK Ademetionine
drug DRUGBANK Methionine
drug DRUGBANK Huperzine B
pathway KEGG Breast cancer
disease MESH breast cancer
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH employment
disease MESH sleep
disease MESH sitting
disease MESH Privacy
disease MESH recurrence
disease MESH uncertainty
disease MESH anxiety
disease MESH Adrenal insufficiency
disease MESH Thyroiditis
disease MESH Hypophysitis
disease MESH Gastritis
disease MESH Colitis
disease MESH Hepatitis
drug DRUGBANK Trametinib
drug DRUGBANK Dabrafenib
drug DRUGBANK Ipilimumab
drug DRUGBANK Pembrolizumab
drug DRUGBANK Nivolumab
drug DRUGBANK Talimogene laherparepvec
disease MESH death
drug DRUGBANK Trestolone
disease MESH COVID 19 pandemic
disease MESH diagnosis
disease MESH lifestyle
disease MESH satisfaction
disease MESH inflammations
disease MESH cancer
pathway KEGG Melanoma
disease MESH melanoma

Original Article

Leave a Comment

Your email address will not be published.